Acrivon Therapeutics (ACRV) Operating Income (2021 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Operating Income of -$19.9 million for Q1 2026, up 8.12% year-over-year from -$18.4 million in Q1 2025, and up 1.06% quarter-over-quarter from -$20.1 million in Q4 2025.
Acrivon Therapeutics (ACRV) Operating Income (2021 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Operating Income for 6 consecutive years, with -$19.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Operating Income rose 8.12% year-over-year to -$19.9 million; the TTM figure through Mar 2026 stood at -$82.4 million (up 11.63% YoY), while the FY2025 annual figure was -$84.1 million, up 5.7% from the prior year.
- Operating Income improved to -$19.9 million in Q1 2026 per ACRV's latest filing, from -$20.1 million in the prior quarter.
- Across five years, Operating Income topped out at -$5.9 million in Q2 2022 and bottomed at -$25.1 million in Q3 2024.
- Historically, Operating Income has averaged -$17.2 million across 5 years, with a median of -$19.7 million in 2025.
- Annual changes were most pronounced in 2022 — Operating Income plunged 258.48% — and 2025, when it gained 21.69%.
- Acrivon Therapeutics' Operating Income stood at -$9.9 million in 2022, then slumped by 111.69% to -$21.1 million in 2023, then declined by 18.53% to -$25.0 million in 2024, then rose by 19.39% to -$20.1 million in 2025, then increased by 1.06% to -$19.9 million in 2026.
- Business Quant data shows ACRV's Operating Income at -$19.9 million in Q1 2026, -$20.1 million in Q4 2025, and -$19.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.29 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 493.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -815.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 325.05 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 231.44 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -1.55 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 133.12 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -375.75 Mn |
| 10 | Acrivon Therapeutics | 92.26 Mn | 92.26 Mn | - | -18.67 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -18.67 Mn |
| Mar 31, 2026 | -19.90 Mn |
| Dec 31, 2025 | -20.12 Mn |
| Sep 30, 2025 | -19.69 Mn |
| Jun 30, 2025 | -22.65 Mn |
| Mar 31, 2025 | -21.66 Mn |
| Dec 31, 2024 | -24.95 Mn |
| Sep 30, 2024 | -25.14 Mn |
| Jun 30, 2024 | -21.44 Mn |
| Mar 31, 2024 | -17.67 Mn |
| Dec 31, 2023 | -21.05 Mn |
| Sep 30, 2023 | -16.14 Mn |
| Jun 30, 2023 | -15.52 Mn |
| Mar 31, 2023 | -14.39 Mn |
| Dec 31, 2022 | -9.95 Mn |
| Sep 30, 2022 | -9.58 Mn |
| Jun 30, 2022 | -5.93 Mn |
| Mar 31, 2022 | -7.21 Mn |
| Dec 31, 2021 | -4.27 Mn |
| Sep 30, 2021 | -2.67 Mn |